Zachary Wegermann, MD Duke University

1. Percutaneous Valve Therapies
in Heart Failure
Zachary Wegermann, MD
Assistant Professor of Medicine
Duke University Hospital
Durham VA Medical Center

2. Disclosures
• Travel/Training: Gore, Edwards, Medtronic
• Site Investigator: Alleviant

3. Outline and Background
• Four Valves with potential for different pathologies
– Stenosis
– Regurgitation
– Mixed stenosis-regurgitation
• Native Valve disease vs Bioprosthetic Valve disease
• There are now transcatheter therapies available for all
4 valves with ongoing clinical trials and continual
innovation.

4. Aortic Valve Disease - Stenosis
Commerical Use Investigational

5. Aortic Valve Disease - Regurgitation
• Currently no commercially available on
label transcatheter treatment options

6. Mitral Valve Disease - Regurgitation

7. Mitral Regurgitation – M-TEER
• Mitral Transcatheter Edge to Edge Repair (M-TEER)
or Transcatheter Mitral Valve Repair (TMVr)
MitraClip PASCAL

8. Transcatheter Mitral Valve Replacement
• No commercially approved valves for TMVR yet.
• Multiple ongoing clinical trials.
Transcatheter Mitral Valve Replacement Therapies - American College of
Cardiology (acc.org)

9. Tricuspid Regurgitation
T-TEER TTVR
TriClip
EVOQUE

10. Tricuspid Valve Interventions – What
Endpoint?
Wegermann, Vemulapalli. 2021.

11. WHAT’S THE BEST APPROACH IN
MULTIVALVULAR HEART
DISEASE?

12. Conclusions
• Commercially available transcatheter
treatment options for all four valves
• Multiple ongoing clinical trials for
transcatheter therapies for valve disease
• We still need more data!